Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2026-02-03 @ 5:34 AM
Study NCT ID:
NCT01522469
Status:
COMPLETED
Last Update Posted:
2024-01-30
First Post:
2012-01-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Sponsor:
Arog Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | View |